ARDELYX, INC.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ARDX$2.93+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit · Incorporated by Reference · Filed | |||||
|---|---|---|---|---|---|
| Number | Exhibit Description | Form | Date | Number | Herewith |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 06/24/2014 | 3.1 | |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation. | 8-K | 06/20/2023 | 3.1 | |
| 3.3 | Second Amended and Restated Bylaws. | 8-K | 08/04/2025 | 3.1 | |
| 10.1† | First Amendment to the Commercial Supply Agreement, dated May 11, 2026, by and between the Company and Catalent Pharma Solutions, LLC. | X | |||
| 10.2† | Second Amendment to the Manufacturing Services Agreement, dated May 15, 2026, by and between the Company and Patheon Pharmaceuticals Inc. | X | |||
| 10.3# | Second Amendment to the Ardelyx, Inc. Amended and Restated 2014 Equity Incentive Award Plan. | 8-K | 06/17/2026 | 10.1 | |
| 31.1 | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101 | The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of June 30, 2026 and December 31, 2025, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026 and 2025, (iii) Condensed Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025, (iv) Condensed Statements of Cash Flows for the six months ended June 30, 2026 and 2025, and (v) Notes to Unaudited Condensed Financial Statements. | X | |||
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101. | X | |||
† Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the SEC upon request.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.